Building My Career by Learning from Challenges, A conversation with Ramona Sequeira, President of Takeda’s U.S. BU

Growing Through Challenges Ramona Sequeira joined Takeda in 2015 as the President of the U.S. BU after working at Eli Lilly for twenty years. Despite the significant responsibility she has as Takeda’s U.S. leader, she radiates positive energy: “I welcome new challenges, and make the most of them. I’m certainly grateful for such opportunities.” One such challenge last year was when she led the U.S. market release of an inflammatory enteritis drug and antidepressant. “Using the resources from old products we created two new products to maximize the benefit of patents, which have so far produced great results.” Also, one […]

Takeda and Cognition Kit partner in study to pilot wearable software in patients with Major Depressive Disorder (MDD)

Cambridge, England, and Deerfield, IL, February 23 2017 – Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition Kit Limited, a joint venture between Cambridge Cognition Holdings PLC and Ctrl Group Limited, announced a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD). Depression (MDD) is the leading cause of disability worldwide, affecting an estimated 350 million people of all ages (1). Cognitive problems are common in major depression and may be under recognized by […]

Making Step Therapy Work for Patients, Providers, and Payers, By, Richard C. Ascroft, RPh, JD, Vice President, Managed Markets and Government Affairs

The use of step therapy protocols by payers to manage pharmacy costs has increased significantly over the past several years. According to Health Strategies Group, in 2015, 39% of health plans used step therapy in at least 12 classes of medications – an increase of 35% over the prior year. At its core, step therapy is about trying to ensure the right patients are getting the right medications at the right point in the care continuum, while also ensuring that lower net cost products are used earlier while higher net cost products are reserved for later lines of care. Step […]

Takeda Welcomes Baltimore Mayor Pugh For Event To Celebrate African-American Contributions During Black History Month, Company Unveils Exhibit Commemorating African-American Contributions To Society

Deerfield, IL, February 9, 2017 –Takeda Pharmaceuticals U.S.A., Inc. today welcomed the recently-elected mayor of Baltimore and nationally-known political leader to its Chicagoland office.  Mayor Cynthia Pugh spoke to an audience of Deerfield-based Takeda employees.  Hundreds of employees were invited to learn about issues of concern in the African-American community as part of the company’s effort to help educate its own employees on diversity and inclusion topics impacting many communities in the U.S.   “We’re delighted to host Mayor Pugh during our celebration of Black History Month as an esteemed source of insight dedicated to promoting economic opportunity for African-Americans,” […]

Takeda Recognized as one of the Global 100 Most Sustainable Corporations for second consecutive year, 2017 Most Sustainable Corporations in the World Index Announced during

Osaka, Japan, January 20, 2017 – Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) is proud to be named by Corporate Knights to the 2017 Global 100 Most Sustainable Corporations in the World Index. Takeda achieved this distinction for the second consecutive year and it is based on 14 key performance indicators, including energy productivity, innovation capacity, safety performance and leadership diversity.   Since 1781, Takeda has been committed to improving the future of healthcare. Inclusion in the Global 100 Index highlights the progress Takeda has made in its corporate responsibility efforts and sustainability planning.   “Takeda is honored to be […]

Takeda Named Best Place To Work for LGBT Equality in the Human Rights Campaign's 2017 Corporate Equality Index

DEERFIELD, Ill., December 7, 2016 – The Human Rights Campaign Foundation has named Takeda a best place to work for lesbian, gay, bisexual and transgender (LGBT) equality.  The company’s perfect score of 100 in the HRC’s 2017 Corporate Equality Index was earned on its first year of submitting an application for this award. The Corporate Equality Index is a national benchmarking tool developed in 2002 that measures an organization’s policies and practices designed to create equity for LGBT employees. According to the Human Rights Campaign, only a few hundred companies globally spanning all industries and nations earn a perfect score each year.  […]

Takeda And Lundbeck Take Innovative Approach To Connecting With People Living With Major Depressive Disorder (MDD), Lighter Blue Facebook Page wins prestigious Bronze award at IPA Best of Health Awards for fostering engagement with MDD community

Deerfield, Ill., December 2, 2016 – On November 29, 2016 Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Lundbeck received a Bronze award at the Institute of Practitioners in Advertising (IPA) Best of Health Awards in the Consumer, Social Media category for Lighter Blue. Lighter Blue, an online community, takes a unique, empathetic approach to educating about Major Depressive Disorder (MDD) in order to help people have informed conversations about their condition with their healthcare providers. The awards are steered by the IPA Healthcare Group, which is comprised of a number of IPA member […]

Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference , Data to feature additional insights into vedolizumab and elements of inflammatory bowel disease (IBD)

Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), will be presented during the Crohn’s & Colitis Foundation of America’s 2016 Advances in Inflammatory Bowel Diseases (AIBD) annual conference, held in Orlando, Florida on December 8-10.   Seventeen Takeda-sponsored posters will be presented during the AIBD meeting, focused on a variety of topics important to the IBD community, including real-world data about vedolizumab treatment.   “As we continue our ongoing investigation and characterization of vedolizumab in […]

Takeda and Koneksa Health Announce Strategic Collaboration to Use Digital Health Tools in Clinical Trials

CAMBRIDGE, Mass. & NEW YORK–Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and Koneksa Health, Inc. (“Koneksa”), an early stage company focused on the integration of real world data into clinical research, today announced an ongoing strategic collaboration to utilize new digital health tools in clinical trials. Using Koneksa’s leading technology data platform, Takeda is integrating biosensor and wearable technology in several of its early stage clinical studies. Koneksa’s technology enables the remote collection of data measures that were previously difficult to obtain, such as patients’ continuous vital signs, activity levels and sleep metrics. These initial clinical studies will also facilitate […]

Results of Study of Febuxostat on the Frequency of Acute Gout Flares in Early Gout, First Clinical Trial Investigating the Effect of Urate-Lowering Therapy on Gout Flares in Early Gout

DEERFIELD, Ill., November 14, 2016 – Today Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), announced Phase 2 study data evaluating febuxostat use in patients with early gout at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Meeting taking place from November 11-16, 2016, in Washington, DC.   The findings were presented as a late-breaking poster entitled “Overall Reduction in Acute Flares During Treatment with Febuxostat Compared with Placebo Over 2 Years in Patients with Early Gout.” The study is the first clinical trial investigating the frequency of acute flares in early gout.   The study examined […]